Investigation of Antioxidant, Anticancer, and Chemopreventive Properties of Hawaiian Grown Māmaki tea (Pipturus albidus)

Alanna Sun¹, Tamara Kondratyuk¹, Supakit Wongwiwatthanakulit², Dianqing Sun¹, and Leng Chee Chang¹

Abstract

Objective Māmaki tea (Pipturus albidus) is a native Hawaiian plant species that is best known for its medicinal uses. It is endemic and only grows on the Hawaiian Islands. We evaluated different extraction methods and investigated antioxidant, anticancer, and/or chemopreventive potential of Māmaki tea. Materials and Methods Fresh Māmaki tea leaves were purchased from Hilo Farmers Market on Big Island. The Ferric Reducing Antioxidant Power (FRAP) assay was used to evaluate the antioxidant activities of selected Hawaii-grown teas, fruits, and vegetables. In addition, chemopreventive assays against tumor necrosis factor (TNF)-α-induced nuclear factor kappa B (NF-κB) and nitric oxide (NO) were performed for these Māmaki tea extracts. Cytotoxicity testing was done using in vitro sulforhodamine B (SRB) assay against lung (LU-1) and breast (MCF-7) cancer cell lines. Results Locally grown red vine Māmaki tea exhibited the highest level (40.0 µM/µg) of antioxidants among the tested locally grown fruits, vegetables, and tea. In addition, when tested at 20 µg/mL, the dehydrated Māmaki tea powders (AS-18), brewed from boiling water, showed the highest NF-κB inhibition (75.0%); and the freeze-dried Māmaki leaf powder (AS-1) brewed using room temperature water had the highest inhibitory activity with 55.5% in the nitrite assay. Furthermore, AS-25, the 100% ethanol extract from dehydrated Māmaki tea leaves exhibited the best anticancer activity with the lowest 71.3% survival of breast cancer cells. Conclusions This work stimulates further studies on the biological properties and medicinal uses of Māmaki tea, and raises community and public awareness to promote Māmaki tea.

Keywords
anticancer, antioxidant, chemopreventive, Māmaki tea, natural product extract, Pipturus albidus

Received: October 18th, 2021; Accepted: January 31st, 2022.

Introduction

Māmaki tea, Pipturus albidus (Hook. & Arn.) Gray, Nettle family (Urticaceae), a native Hawaiian plant species,¹ is well known for its medicinal uses. It is endemic to and only grows on the Hawaiian Islands.²,³ Māmaki tea is reported to contain diverse antioxidants, such as catechins, chlorogenic acid, and rutin,⁴,⁵ along with antibacterial and antiviral activities.⁶ The medicinal uses of Māmaki tea range from antioxidant, mild natural laxative, anti-allergic effect, promoting cardiovascular and liver health, to decreasing stress levels.²,³ Antioxidants also play an important role in cancer chemoprevention and development in laboratory and animal model studies.⁷,⁸ As such, in addition to evaluating the antioxidant activity of Māmaki tea, we are also interested in investigating anticancer and chemopreventive potential associated with Māmaki tea extracts.⁹ Specifically in this work, we examined various preparations and brewing methods (e.g., different temperatures, water and ethanol extraction, tea powders and leaves, and dehydrated or freeze-dried) and investigated which method may produce the best medicinal properties of Māmaki tea.

Results

Antioxidant Activity

The Ferric Reducing Antioxidant Power (FRAP) values of Māmaki tea and fruit extracts were determined in two triplicates

1Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, Hilo, HI, USA
2Department of Pharmacy Practice, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, Hilo, HI, USA

Corresponding Author:
Leng Chee Chang, PhD, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, 200 W. Kawili St., Hilo, HI 96720, USA.
Email: lengchee@hawaii.edu
temperature 100% ethanol extract sample (AS-25) from with relatively low survival rates (73.9 and 77.5%). The room tea loose leaves showed the most potent cytotoxic activity extract samples (AS-12 and AS-13, respectively) from green. It is worthwhile mentioning that the warm and boiling water % survival with the higher % survival being less or not toxic. Cytotoxicity data are shown in Table 1 and reported as tion. Cytotoxicity data are shown in Table 1. Initial determinations for all these assays were carried out at a sample concentration of 20 µg/mL.

**NF-κB Inhibition.** Among all the extract samples tested, overall the dehydrated Mâmaki tea powders showed the highest inhibition activities in the NF-κB assay. For example, the room temperature, warm, and boiling tea samples using the dehydrated Mâmaki tea powder showed over 60% of inhibition against NF-κB. Notably, the room temperature (AS-16) and boiling water (AS-18) samples from the dehydrated Mâmaki tea powder had the highest percentages of inhibition of 73.7% and 75.0%, respectively. The freeze-dried Mâmaki tea whole leaves (Sample AS-6), extracted from room temperature water, also showed 60.6% inhibition. Among the tea samples extracted with warm water (60 °C), the dehydrated Mâmaki tea powder (AS-17) had the highest percentage of inhibition (62.7%). By comparing the freeze-dried Mâmaki teas, samples AS-3, AS-4, and AS-5 extracted with boiling water and ethanol exhibited higher inhibition than those (AS-1 and AS-2) from room temperature and warm water. In addition, the 70% ethanol sample (AS-24) from dehydrated Mâmaki tea whole leaves also showed 68.4% inhibition.

**Nitric Oxide (NO) Inhibition.** In general, all extract samples showed less than 60% inhibition of NO production in LPS-stimulated RAW 264.7 cells. However, the ethanol extract samples (e.g., the 100% ethanol extract from freeze-dried Mâmaki tea sample, AS-10; the 70% ethanol extract from dehydrated Mâmaki tea sample, AS-24; and the 100% ethanol extract from dehydrated Mâmaki tea sample, AS-25) all showed over 50% inhibition when tested at 20 µg/mL. Interestingly, the room temperature water sample (AS-1) from freeze-dried Mâmaki tea powders also showed the most potent percentage inhibition (55.5%).

**Cytotoxicity Effect.** When all Mâmaki tea extract samples were tested at 20 µg/mL against two representative cancer cell lines (lung and breast cancer cells), most samples were largely inactive, exhibiting over 80% survival toward cancer cell proliferation. Cytotoxicity data are shown in Table 1 and reported as % survival with the higher % survival being less or not toxic. It is worthwhile mentioning that the warm and boiling water extract samples (AS-12 and AS-13, respectively) from green tea loose leaves showed the most potent cytotoxic activity with relatively low survival rates (73.9 and 77.5%). The room temperature 100% ethanol extract sample (AS-25) from dehydrated Mâmaki tea leaves had the best cytotoxic activity with the lowest % survival (71.3%) against breast cancer cells.

**Discussion**

In the antioxidant study, fruits and vegetables were peeled, seeded, juiced, and then filtered. The water-soluble filtrates were collected and freeze-dried for testing. This sample preparation could cause lower than actual antioxidant activities observed, because antioxidants could be found in peels, seeds, and pulps with different distribution profiles. Different brewing methods can also determine the amount of antioxidants extracted from Mâmaki tea and, therefore, the chosen brewing method in this antioxidant study may not be the most optimal one. Consistent with the previous report describing the identification of flavonoids and polyphenols in Mâmaki tea, the current data show Mâmaki tea extract had the highest antioxidant activity (40.0 µM/µg) among test extract samples, suggesting it may contain a rich source of natural antioxidants such as (+) catechins and rutin.

With regard to suppressing NF-κB activation, the room temperature (AS-16) and boiling water (AS-18) samples from the dehydrated Mâmaki tea powders had the highest percentages of inhibition of 73.7% and 75.0%, respectively, among all the test samples. In addition, the room temperature, warm, and boiling water tea samples using the dehydrated Mâmaki tea powder, along with the freeze-dried Mâmaki tea whole leaves (Sample AS-6), showed > 60% of inhibition. The dehydrated Mâmaki tea powder (AS-17) exhibited the highest percentage (62.7%) of inhibition among the warm temperature tea samples. From the freeze-dried tea samples, AS-3, AS-4, and AS-5 from boiling water and ethanol showed higher inhibition than AS-1 and AS-2 from room temperature and warm water. Finally, AS-24, the 70% ethanol sample from dehydrated Mâmaki tea whole leaves, showed 68.4% inhibition against NF-κB. In the NO inhibition assay, all samples generally showed < 60% of inhibition when tested at 20 µg/mL. In contrast, the ethanol extract samples such as AS-10 (100% ethanol extract from freeze-dried Mâmaki tea), AS-24 (70% ethanol extract from dehydrated Mâmaki tea), and AS-25 (100% ethanol extract from dehydrated Mâmaki tea) all exhibited > 50% of inhibition at 20 µg/mL. Notably, green tea extracts have been previously evaluated in clinical studies as an effective supplement with cancer chemopreventive potential.

In cell-based cytotoxicity assays against representative lung and breast cancer cells, most samples were largely inactive with > 80% survival toward cancer cell proliferation when tested at 20 µg/mL. The 100% ethanol extract sample from dehydrated Mâmaki tea leaves, AS-25, showed the lowest survival percentage (71.3%) against breast cancer cells. The overall high % survival and low cytotoxicity activity may be attributed to weak activity and/or relatively low amounts of active compounds in the extract samples tested. On the basis of these data, there are no apparent correlations among chemopreventive NF-κB and NO inhibition and cytotoxic activity. Interestingly, polyphenols
Table 1. Activities of Mämaki Tea Extract Samples AS-1 to AS-25 Evaluated in Anticancer and Chemopreventive Assays.

| Sample ID<sup>a</sup> | NF-κB assay | Nitrite assay | Cytotoxicity assay (% survival) |
|-----------------------|-------------|--------------|-------------------------------|
|                        | % inhibition | % survival   | % inhibition                  | % survival | Lung cancer cells (LU-1) | Breast cancer cells (MCF-7) |
| AS-1                  | 27.4 ± 10.9 | 82.4 ± 2.6 | 255.5 ± 0.4                  | 95.4 ± 2.0 | 84.2 ± 2.0               | 80.1 ± 7.1                  |
| AS-2                  | 28.9 ± 3.3  | 90.2 ± 5.5 | 44.5 ± 10.8                  | 90.6 ± 15.8| 95.8 ± 5.0               | 95.2 ± 9.2                  |
| AS-3                  | 54.9 ± 1.0  | 90.6 ± 8.0 | 39.0 ± 14.9                  | 96.6 ± 7.4 | 94.1 ± 8.9               | 96.0 ± 6.1                  |
| AS-4                  | 56.9 ± 7.0  | 102.0 ± 9.7| 38.2 ± 5.6                   | 96.2 ± 9.1 | 97.2 ± 8.2               | 97.2 ± 8.1                  |
| AS-5                  | 61.9 ± 4.4  | 105.3 ± 8.3| 15.3 ± 17.1                  | 95.0 ± 10.5| 98.5 ± 12.3              | 99.3 ± 7.4                  |
| AS-6                  | 60.6 ± 3.8  | 88.2 ± 7.0 | 4.7 ± 9.7                    | 98.8 ± 17.7| 99.8 ± 10.2              | 99.2 ± 9.4                  |
| AS-7                  | 39.4 ± 6.4  | 101.2 ± 11.4| -1.8 ± 1.1                   | 96.2 ± 13.0| 97.9 ± 11.3              | 99.4 ± 5.8                  |
| AS-8                  | 59.7 ± 4.8  | 96.0 ± 10.8| 17.1 ± 7.8                   | 98.1 ± 9.8 | 99.4 ± 11.0              | 102.9 ± 2.9                 |
| AS-9                  | 58.3 ± 2.8  | 86.4 ± 12.2| 36.1 ± 6.3                   | 101.2 ± 6.4| 92.2 ± 18.1              | 99.0 ± 2.1                  |
| AS-10                 | 38.1 ± 12.1 | 81.2 ± 8.0 | 52.6 ± 6.0                   | 96.8 ± 9.7 | 96.8 ± 11.3              | 102.8 ± 2.7                 |
| AS-11                 | 43.1 ± 1.7  | 63.2 ± 11.3| 49.2 ± 4.1                   | 94.8 ± 16.8| 82.1 ± 26.9              | 87.4 ± 3.6                  |
| AS-12                 | 31.3 ± 0.6  | 91.2 ± 8.5 | 48.7 ± 4.1                   | 98.0 ± 8.4 | 76.2 ± 7.7               | 73.9 ± 6.6                  |
| AS-13                 | 46.6 ± 5.6  | 84.7 ± 11.8| 47.6 ± 2.6                   | 60.9 ± 3.9 | 77.5 ± 0.6               | 82.3 ± 5.4                  |
| AS-14                 | 32.6 ± 6.1  | 64.1 ± 12.0| 39.7 ± 3.4                   | 98.1 ± 4.3 | 86.7 ± 3.0               | 94.8 ± 0.5                  |
| AS-15                 | 62.2 ± 3.1  | 61.4 ± 11.8| 36.8 ± 2.2                   | 100.2 ± 2.6| 88.1 ± 0.3               | 93.8 ± 4.3                  |
| AS-16                 | 73.7 ± 6.8  | 55.9 ± 9.5 | 32.1 ± 5.2                   | 101.3 ± 3.6| 101.5 ± 0.7              | 102.7 ± 5.0                 |
| AS-17                 | 62.7 ± 7.3  | 53.4 ± 2.6 | 27.6 ± 12.3                  | 100.1 ± 3.5| 102.5 ± 4.1              | 103.8 ± 1.4                 |
| AS-18                 | 75.0 ± 8.4  | 43.3 ± 1.5 | 18.4 ± 14.1                  | 102.2 ± 9.9| 102.1 ± 2.8              | 105.8 ± 2.8                 |
| AS-19                 | 28.6 ± 8.4  | 47.4 ± 3.8 | 45.4 ± 10.8                  | 102.5 ± 0.3| 102.8 ± 1.8              | 102.7 ± 3.5                 |
| AS-20                 | 56.2 ± 1.8  | 45.6 ± 0.0 | 35.0 ± 4.1                   | 103.2 ± 0.3| 106.5 ± 1.9              | 101.9 ± 4.2                 |
| AS-21                 | 45.3 ± 1.0  | 49.9 ± 8.2 | 30.5 ± 9.7                   | 103.6 ± 0.9| 101.5 ± 3.3              | 102.0 ± 3.7                 |
| AS-22                 | 3.0 ± 13.1  | 49.4 ± 8.4 | 22.6 ± 5.2                   | 104.1 ± 1.6| 104.2 ± 0.5              | 104.2 ± 3.3                 |
| AS-23                 | 53.8 ± 11.1 | 56.5 ± 8.1 | 44.7 ± 0.0                   | 105.0 ± 0.2| 103.6 ± 2.6              | 100.5 ± 3.2                 |
| AS-24                 | 68.4 ± 3.1  | 96.4 ± 11.5| 50.5 ± 4.5                   | 101.7 ± 3.0| 100.1 ± 1.8              | 95.6 ± 9.1                  |
| AS-25                 | 37.0 ± 8.5  | 97.1 ± 9.5 | 52.1 ± 2.2                   | 70.5 ± 11.1| 85.1 ± 2.5               | 71.3 ± 1.4                  |
| Positive controls     | 5.1 ± 0.8 µM<sup>b</sup> | 8.6 to 19.7 µM<sup>c</sup> | 30.8 to 68.3 nM<sup>d</sup> |

<sup>a</sup>Refer to Table 2 for detailed sample preparation information of AS-1 to AS-25.
<sup>b</sup>IC<sub>50</sub> values of N-tert-phenylalanine chloromethyl ketone (TPCK) in the NF-κB assay using human embryonic kidney HEK-293 cells.
<sup>c</sup>IC<sub>50</sub> values of L-tert-monomethyl arginine (L-NMMA) in the nitrite assay using LPS-stimulated RAW 264.7 murine macrophage cells.
<sup>d</sup>IC<sub>50</sub> values of staurosporine, a microbial alkaloid, in the cytotoxicity assay.

Abbreviations: NF-κB: nuclear factor kappa B.

and/or tea beverage may also have a synergistic effect with chemotherapeutic agents to improve treatment outcome and reduce adverse effects in cancer chemotherapy. Collectively, Mämaki tea is a Hawaiian plant that has been traditionally used by native Hawaiians as a health remedy. So far, very limited scientific and clinical studies have been done toward Mämaki tea and its health benefits. Thus, we see a window of opportunity to focus on Mämaki tea studies and obtain evidence-based scientific data to support its medicinal and therapeutic uses. This way, we can scientifically promote Mämaki tea, a unique product from Hawaii, to the rest of the world.

Conclusions

In conclusion, with regard to antioxidant evaluation, the antioxidant activity of Mämaki tea was measured as 40.0 µM/µg, showing the highest antioxidant level among the plants tested. In anticancer and chemopreventive studies, the Mämaki tea sample was generally more active than the green tea sample. Specifically, the room temperature and boiling water extract samples from the dehydrated Mämaki tea powder demonstrated the highest percentage inhibitions ranging from 73.7% to 75.0% in the NF-κB assay; the freeze-dried Mämaki leaf powders brewed at room temperature had the highest inhibitory activity in the nitrite assay. In the cytotoxicity assay, the 100% ethanol extract sample (AS-25) from dehydrated Mämaki tea leaves showed the best activity with the lowest survival against breast cancer cells (71.3%). Chemical and metabolomic profiling of these Mämaki tea extract samples are ongoing and will be reported in due course.

Materials and Methods

Testing Materials

Fresh Mämaki tea (P. albidus) leaves, fresh papaya, fresh cucumber, fresh lilikoi, and fresh lemon were purchased from Big Island Hilo Farmers Market. The Mämaki tea plant was identified by Dr. Leng Chee Chang. A voucher specimen (No. MKK 002) was deposited in the Natural Product Chemistry Laboratory, the Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo.
Table 2. A Summary of Tea Sample Preparation Types, Extraction Temperature, and Solvent Used.

| Sample ID | Tea sample type (1.5 g per sample) | Extraction temperature and solvent (40 mL) |
|-----------|-----------------------------------|------------------------------------------|
| AS-1      | Freeze-dried Māki tea powders      | Water (27 °C)                            |
| AS-2      | Freeze-dried Māki tea powders      | Water (60 °C)                            |
| AS-3      | Freeze-dried Māki tea powders      | Water (100 °C)                           |
| AS-4      | Freeze-dried Māki tea powders      | 70:30 EtOH/H2O (27 °C)                   |
| AS-5      | Freeze-dried Māki tea leaves       | EtOH (27 °C)                             |
| AS-6      | Freeze-dried Māki tea leaves       | Water (27 °C)                            |
| AS-7      | Freeze-dried Māki tea leaves       | Water (60 °C)                            |
| AS-8      | Freeze-dried Māki tea leaves       | Water (100 °C)                           |
| AS-9      | Freeze-dried Māki tea leaves       | 70:30 EtOH/H2O (27 °C)                   |
| AS-10     | Freeze-dried Māki tea leaves       | EtOH (27 °C)                             |
| AS-11     | Green tea loose leaves             | Water (27 °C)                            |
| AS-12     | Green tea loose leaves             | Water (60 °C)                            |
| AS-13     | Green tea loose leaves             | Water (100 °C)                           |
| AS-14     | Green tea loose leaves             | 70:30 EtOH/H2O (27 °C)                   |
| AS-15     | Green tea loose leaves             | EtOH (27 °C)                             |
| AS-16     | Dehydrated Māki tea powders        | Water (27 °C)                            |
| AS-17     | Dehydrated Māki tea powders        | Water (60 °C)                            |
| AS-18     | Dehydrated Māki tea powders        | Water (100 °C)                           |
| AS-19     | Dehydrated Māki tea powders        | 70:30 EtOH/H2O (27 °C)                   |
| AS-20     | Dehydrated Māki tea powders        | EtOH (27 °C)                             |
| AS-21     | Dehydrated Māki tea leaves         | Water (27 °C)                            |
| AS-22     | Dehydrated Māki tea leaves         | Water (60 °C)                            |
| AS-23     | Dehydrated Māki tea leaves         | Water (100 °C)                           |
| AS-24     | Dehydrated Māki tea leaves         | 70:30 EtOH/H2O (27 °C)                   |
| AS-25     | Dehydrated Māki tea leaves         | EtOH (27 °C)                             |

Chemicals, Reagents, and Cell Cultures

Solvents and reagents were purchased from either Sigma-Aldrich or Fisher Scientific and used without further purification. These chemicals include ethanol, dimethylsulfoxide (DMSO), acetate buffer (300 mM, pH 3.6), 2,4,6-tripyridyl-s-triazine (TPTZ), FeCl₃•6H₂O, and FeSO₄•7H₂O; the Luciferase Reporter Assay System was purchased from Promega. Dulbecco’s modified Eagle media (DMEM), antibiotic-antimycotic solution (100×), and fetal bovine serum (FBS) were purchased from Invitrogen, and phosphate-buffered saline (PBS), Griess reagent [1:1 mixture (v/v) of 1% sulfanilamide in H₃PO₄ and N-(1-naphthyl)ethylenediamine dihydrochloride solution], sodium nitrite, sulfrodamine B (SRB), trichloroacetic acid solution, acetic acid solution, lipopolysaccharide (LPS), and Tris·HCl from Sigma-Aldrich. The following cell lines were used: RAW 264.7 murine macrophage cells, human embryonic kidney 293 cells, and lung (LU-1) and breast (MCF-7) cancer cell lines. Unless otherwise stated, all cell lines were obtained from the American Type Culture Collection (ATCC), and grown in media supplemented with penicillin G (100 units/mL), streptomycin (100 mg/mL), and heat-inactivated FBS at 37 °C in 5% CO₂ in a humidified incubator. Stock cell cultures were prepared and aliquots were stored in liquid nitrogen. During the course of the study, cells were used below a passage number of 20. No significant changes were noted in morphology or growth characteristics.

Supplies and Instruments

Project supplies and instruments used in this work include a 96-Well Microtiter Plate, Nesco® Professional Dehydrator, Ninja® Food Processor, GeneVac EZ-2 Evaporator, LABCONCO FrezZone Plus 12 Liter Cascade Console Freeze Dry System, Humidified Air Incubator, and ELY p800 Absorbance Micro Reader (BioTek Instruments). The luminometer (Lumistar Galaxy microplate reader) was programed to dispense 25 µL of the luciferase assay reagent into each well and the amount of light produced was measured.

Testing Materials Preparation

Antioxidant Study

Preparing Māki tea, Fruits, and Vegetables. Fresh Māki tea leaves, two papayas, four cucumbers, three medium-sized lemons, and five lilikoi were collected. Fresh Māki tea leaves were dried in a lyophilizer for 48 h. The dried Māki tea leaves (15 g) were soaked for 30 min in 300 mL of warm water (60 °C). After 30 min, the tea was filtered and poured into a separate bowl. The soaking and filtering processes were repeated twice. All of the filtrates was next combined and left in a freezer until it was completely frozen. The frozen tea filtrate was thawed, and the filtrate was left in the freezer until frozen. The frozen filtrate was lyophilized to let it freeze dry. Once the samples turned into powder and/or residue, they were ready to use. (On average, it took about 5 days to completely freeze dry the frozen juice.)

Sample Preparation. All the freeze-dried test materials were weighed and recorded, and subsequently transferred into
vials, which were stored in a refrigerator for testing. Next, the Māmaki tea solution (10 mg/mL) was prepared by dissolving 10 mg of freeze-dried Māmaki tea in 1 mL of deionized water. The 1 mg/mL Māmaki tea solution was prepared by mixing 100 μL of the tea solution (10 mg/mL) with 900 μL of deionized water. The remaining 10 and 1 mg/mL vegetable water. The 1 mg/mL Māmaki tea solution was prepared by dissolving in DMSO to make an initial sample concentration of 4 mg/mL; these were further diluted to give a final test concentration of 20 μg/mL. Briefly, test and control solutions (10 μL per well), with control groups containing a 10% DMSO aqueous solution, were plated in microtiter plates, followed by additional 1/20 dilutions by adding 190 μL cell solution into each well. Each test sample was evaluated in triplicate.

Anticancer and Chemopreventative Study

Preparing Māmaki tea Samples Using Different Brewing Methods. Portions of fresh Māmaki tea leaves were dried in a lyophilizer for 72 h. The rest of the fresh Māmaki tea leaves were dried in a dehydrator at the lowest temperature setting for around 3.5 h. Next, half of either the freeze-dried or dehydrated tea leaves were blended into powders using a food processor. The Māmaki tea samples used in this study include: (i) dehydrated Māmaki tea powders; (ii) dehydrated Māmaki tea leaves; (iii) freeze-dried Māmaki tea powders; and (iv) freeze-dried Māmaki tea leaves. Brewing methods included room temperature water (27 °C), warm water (60 °C), boiling water (100 °C), 70% ethanol in water, and 100% ethanol.

Twenty-five tea samples AS-1 to 25 were weighed and stored in tea bags with 1.5 g per sample. Specifically, samples AS-1 to 5 are freeze-dried Māmaki tea powders; AS-6 to 10 are freeze-dried Māmaki tea leaves; AS-11 to 15 are green tea loose leaves for comparison; AS-16 to 20 are dehydrated Māmaki tea powders; and AS-21 to 25 are dehydrated Māmaki tea leaves (Table 2).

Forty mL of room temperature (27 °C) water was added to each polypropylene centrifuge tube containing samples AS-1, 6, 11, 16, and 21, respectively. The resulting centrifuge tube was shaken every 10 min during a 30 min period. After 30 min, the liquid was decanted, ensuring that most tea solution was drained from each tea bag. Tea solutions were collected and stored in labeled centrifuge tubes for later experiments. Accordingly, 40 mL of warm temperature (60 °C) water, boiling (100 °C) water, room temperature 70% ethanol in water, and room temperature 100% ethanol were added to each polypropylene centrifuge tube containing samples AS-2, 7, 12, 17, and 22; samples AS-3, 8, 13, 18, and 23; samples AS-4, 9, 14, 19, and 24; and samples AS-5, 10, 15, 20, and 25, respectively. Each of the resulting centrifuge tubes was shaken every 10 min during a 30 min period. After 30 min, the liquid was decanted, ensuring that most tea solution was drained from each tea bag. Tea solutions were collected and stored in labeled centrifuge tubes for later experiments.

Tea solutions from samples AS-1 to 25 were evaporated using a GeneVac evaporator and/or a lyophilizer instrument to remove water and/or ethanol. The dried powders from each sample were subsequently obtained and weighed.

Preparation of Samples for Assays. Test samples were weighed and dissolved in DMSO to make an initial sample concentration of 4 mg/mL; these were further diluted to give a final test

Assay Methods and Protocols

Antioxidant FRAP Assay

The ferric ion-reducing/antioxidant power (FRAP) assay is a simple, quick, and inexpensive protocol to quantify a sample’s total antioxidant activity. The reducing ability of antioxidants is tested by reducing ferric tripyridyltriazine (TPTZ) complex to the formation of ferrous TPTZ form. The absorbance change of a given sample at 595 nm can then be used to calculate its antioxidant potential by comparing it with a standard.

The FRAP reagent was produced by mixing 300 mM acetate buffer (pH 3.6), 10 mM FeCl3·6H2O, 10 mM FeSO4·7H2O (molecular weight: 278.01 g/mol) was weighed and dissolved in 10 mL of deionized water to make a 1 M stock solution. The 1000, 800, 600, 400, 200, 100, and 50 μM solutions were prepared accordingly by serial dilution. The FRAP reagent (150 μL) was added to each well of the 96-well plate. A blank reading was taken at 595 nm using a microplate reader (BioTek ELY 800 Absorbance Reader). Twenty μL of the test sample in triplicate and 20 μL of standards of known Fe (II) concentrations in triplicate were added to the 96-well plate accordingly. After incubating at room temperature for 8 min, the plate was read at 595 nm. This process was repeated once so that six sets of data for each test sample were obtained. Catechin was used as a positive control.

Chemopreventive and Cytotoxicity Assays

Chemopreventive potential was first measured using the luciferase NF-κB assay. This assay is determined by emitting light via the oxidative conversion of luciferin to oxyluciferin through electron transition. In addition, the Māmaki tea extract samples were also tested against two cancer cell lines in cell-based assays. The effect of extracts on proliferation of cultured cancer cells was tested using the cellular protein-staining SRB assay. The chemopreventive property was also measured using the NO colorimetric assay. NO functions as an important physiological messenger and effector molecule and is present in diverse biological systems, such as neuronal, immunological, and cardiovascular tissues. One strategy to evaluate the NO formation is to test the level of nitrite (NO2−), one of two major products of NO.
**NF-κB Luciferase Assay**

This assay was performed using NF-κB reporter stably transfected human embryonic kidney cells 293 (HEK-293) from Panomics Inc. (Fremont, CA). This cell line contains chromosomal integration of a luciferase reporter construct, regulated by an NF-κB response element. The gene product, luciferase enzyme, reacts with luciferase substrate, emitting light, which can be detected with a luminometer. Recombinant, human tumor necrosis factor (TNF)-α, expressed in Escherichia coli, (Calbiochem, Gibbstown, NJ) was used as an activator at 2 ng/mL (0.14 nM in the incubation mixture). After a 6 h incubation with tested samples, the reaction was stopped by adding 50 µL Reporter Lysis Buffer (Promega) and frozen overnight at −80 °C. The cells were thawed and the inhibiting activity was measured using a luminometer LUMIstar Galaxy (BMG) and Luc assay system from Promega (Madison, WI). N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) was used as a positive control.20

**Nitrite Assay to Measure NO Production in LPS-Stimulated RAW 264.7 Murine Macrophage Cells**

Because of the instability of NO and its subsequent conversion to nitrite, the NO level in the cultured media was estimated by measuring the nitrite level. In brief, mouse macrophage RAW 264.7 cells from the American Type Culture Collection (ATCC®TIB-71™) were incubated in 96-well plates at 37 °C, in a 5% CO2 humidified incubator for 24 h. Cells were next treated with various tea extract samples for 15 min first, followed by treatment with or without LPS (1 µg/mL) for an additional 20 h. After the incubation, nitrite released in the cultured media was measured using Griess reagent [1:1 mixture (v/v) of 1% sulfanilamide in 5% H3PO4 and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride solution], and absorbance was measured at 540 nm with a microplate reader. The concentration of nitrite was calculated using a standard curve created with known concentrations of sodium nitrite. To evaluate the cytotoxic effects of test samples with RAW 264.7 cells under the same experimental conditions, the SRB assay was performed.21,23 L-NαG-monomethyl arginine citrate was used as a positive control.20

**Sulforhodamine B (SRB) Cytotoxicity Assay**

Mamaki tea extract samples were evaluated for cytotoxic activity using an in vitro SRB assay against breast (MCF-7) and lung (LU-1) cancer cell lines.26 In brief, cancer cells (1 × 10⁴ cells in 190 µL of the complete media) were plated in 96-well plates overnight and then treated with test samples and incubated at 37 °C in a 5% CO2 incubator for 72 h. All samples were assayed in triplicate. After the incubation, cells were fixed with 10% trichloroacetic acid solution for 30 min and stained with 0.4% SRB in 1% acetic acid solution for 30 min. After washing with 1% acetic acid solution, protein-bound SRB was dissolved in 10 mM Tris buffer (pH 10.0) and optical densities were determined at 515 nm. The effect of extract samples on cell survival was evaluated as % survival in comparison with vehicle (DMSO)-treated control cells.21,22

**Declaration of Conflicting Interest**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical Approval**

Ethical Approval is not applicable for this article.

**Statement of Human and Animal Rights**

This article does not contain any studies with human or animal subjects.

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**Trial Registration**

Not applicable, because this article does not contain any clinical trials.

**ORCID iD**

Dianqing Sun https://orcid.org/0000-0001-7330-1742

**References**

1. Little EL,Jr, Skolmen RG. Common forest trees of Hawaii (native and introduced). Agriculture Handbook, Forest Service, U.S. Dept. of Agriculture, 1989; No. 679:104. https://www.fs.fed.us/pnw/publications/documents/misc/ah679.pdf.
2. Mamaki tea – Hawaiian Chai. Accessed January 12, 2022. https://www.mauimedicinal.com/collections/mamaki.
3. Mamaki, Kona Coffee and Tea Company. Accessed January 12, 2022. www.konacoffeandtea.com/blog/mamaki-tea-hawaii.
4. Kartika H, Li QX, Wall MM, Nakamoto ST, Iwaoka WT. Major phenolic acids and total antioxidant activity in mamaki leaves, Pipturus albidus. J Food Sci. 2007;72(9):S696-S701. doi:10.1111/j.1750-3841.2007.00530.x.
5. Kartika H, Shido J, Nakamoto ST, Li QX, Iwaoka WT. Nutrient and mineral composition of dried mamaki leaves (Pipturus albidus) and infusions. J Food Compos Anal. 2011;24(1):44-48. doi:10.1016/j.jfca.2010.03.027.
6. Locher CP, Burch MT, Mower HF, et al. Anti-microbial activity and anti-complement activity of extracts obtained from selected hawaiian medicinal plants. J Ethnopharmacol. 1995;49(1):23-32. https://doi.org/10.1016/0378-8741(95)01299-0.
7. National Cancer Institute. Antioxidants and cancer prevention. Accessed January 12, 2022. https://www.cancer.gov/about-cancer/causes-prevention/risk/antioxidants-fact-sheet.
8. Kundu JK, Surh Y-J. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1):15-30. doi:10.1016/j.mrrev.2008.03.002.
9. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer efficacy of polyphenols and their combinations. *Nutrients*. 2016;8(9):552. doi:10.3390/nu8090552.

10. Guo C, Yang J, Wei J, Li Y, Xu J, Jiang Y. Antioxidant activities of peel, pulp and seed fractions of common fruits as determined by FRAP assay. *Nutr Res*. 2003;23(12):1719-1726. doi:10.1016/j.nutres.2003.08.005.

11. Grzesik M, Naparło K, Bartosz G, Sadowska-Bartosz I. Antioxidant properties of catechins: comparison with other antioxidants. *Food Chem*. 2018;241:480-492. doi:10.1016/j.foodchem.2017.08.117.

12. Shimizu M, Fukutomi Y, Ninomiya M, et al. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. *Cancer Epidemiol Biomarkers Prev*. 2008;17(11):3020-3025. doi:10.1158/1055-9965.epi-08-0528.

13. Stingl JC, Ettrich T, Muche R, et al. Protocol for minimizing the risk of metachronous adenomas of the colorectum with Green tea extract (MIRACLE): a randomised controlled trial of Green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. *BMC Cancer*. 2011;11:360. doi:10.1186/1471-2407-11-360.

14. Cao J, Han J, Xiao H, Qiao J, Han M. Effect of tea polyphenol compounds on anticancer drugs in terms of anti-tumor activity, toxicity, and pharmacokinetics. *Nutrients*. 2016;8(12):762. doi:10.3390/nu8120762.

15. Fukuchi A, Sang-ngern M, Zhang M, et al. Evaluation of cytotoxic and antioxidant activity of fucose-containing sulfated polysaccharide from hawaiian marine algae. *Bull Health Sci Technol*. 2017;15(2):15-31.

16. Griffin SP, Bhagoori R. Measuring antioxidant potential in corals using the FRAP assay. *J Exp Mar Bio Ecol*. 2004;302(2):201-211. doi:10.1016/j.jembe.2003.10.008.

17. Kaushik A, Jitta C, Kaushik JJ, Zeray R, Ambesair A, Beyene L. FRAP (Ferric reducing ability of plasma) assay and effect of *Diplazium esculentum* (retz) Sw. (a Green vegetable of north India) on central nervous system. *Indian J Nat Prod Resour*. 2012;3(2):228-231.

18. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. *Anal Biochem*. 1996;239(1):70-76. doi:10.1006/abio.1996.0292.

19. Campbell KJ, Perkins ND. Regulation of NF-κB function. *Biochem Soc Symp*. 2006;73:165-180. doi:10.1042/bss0730165.

20. Kendratyuk TP, Park E-J, Yu R, et al. Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents. *Mar Drugs*. 2012;10(2):451-464. doi:10.3390/md10020451.

21. Shen L, Park E-J, Kendratyuk TP, et al. Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents. *Bioorg Med Chem*. 2011;19(21):6182-6195. doi:10.1016/j.bmc.2011.09.020.

22. You M, Wickramaratne DBM, Silva GL, et al. (−)-Roemerine, an aporphine alkaloid from *Annona senegalensis* that reverses the multidrug-resistance phenotype with cultured cells. *J Nat Prod*. 1995;58(4):598-604. doi:10.1021/np50118a021.

23. Park E-J, Cheenpracha S, Chang LC, Pezzuto JM. Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by epimuqubilin A via IKK/IκB/NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells. *Phytochem Lett*. 2011;4(4):426-431. doi:10.1016/j.phytol.2011.07.009.

24. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. *Annu Rev Pharmacol Toxicol*. 2001;41(1):203-236. doi:10.1146/annurev.pharmtox.41.1.203.

25. Tuteja N, Chandra M, Tuteja R, Misra MK. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. *J Biomed Biotechnol*. 2004;2004(4):498591. doi:10.1155/S1110724304402034.

26. Orelana EA, Kasinski AL. Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. *Bio Protoc*. 2016;6(21):e1984. doi:10.21769/BioProtoc.1984.